Type | Public (NASDAQ: AMLN) |
---|---|
Industry | Biotechnology |
Founded | 1987 |
Headquarters | San Diego, California, USA |
Key people | Daniel M. Bradbury[1] |
Products | Symlin (pramlintide) Byetta (exenatide) |
Revenue | US$758M (FY 2009)[2] |
Operating income | US$-173M (FY 2009)[2] |
Net income | US$-186M (FY 2009)[2] |
Total assets | US$1.73B (FY 2009)[3] |
Total equity | US$423M (FY 2009)[3] |
Employees | 1,900 [1] |
Website | www.amylin.com |
Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces two drugs, Symlin (pramlintide acetate) and Byetta (exenatide). Amylin also is working on producing a drug based on Leptin.[4]